KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer

• DOI: 10.1371/journal.pone.0239806
• Publication Date: 2020-10-01T17:34:39Z
• Authors: Peter Jo; Markus Bernhardt; Manuel Nietert; Alexander König; Azadeh Azizian; Markus A. Schirmer; Marian Grade; Julia Kitz; Kirsten Reuter-Je...; Michael Ghadimi; Philipp Ströbel; Hans-Ulrich Schil...; Jochen Gaedcke
• Keywords: Concordance; Primary tumor

Introduction Oncogenic mutation within the KRAS gene represents a negative predictor for treatment response to anti-epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Recently, we have shown no relevant heterogeneity status and between pre- posttherapeutic samples from primary tumor locally advanced rectal The aim of this study was evaluate intertumoral corresponding metastasis or local recurrence similar cohort ideal representative tissue testing. Materials methods analyzed 47 cancer, which were enrolled CAO/ARO/AIO-94 CAO/ARO/AIO-04 trial. Mutations codons 12, 13, 61 by using RGQ PCR Kit (therascreen® test). Six needed be excluded due incomplete follow up data. 11 showed relapse disease during presented distant metastases recurrence. DNA areas metastatic obtained formalin-fixed paraffin-embedded specimens. Results mean patient age 64.13 ± 10.64 years. In total, 19 (46.34%) tumor. Of eleven recurrence, five whereas six had wildtype status. Metastatic localizations included liver (n = 2), lung 4), 1), + 3), 1). For these paired data available tissue, significant concordance detected 81.18% (9/11) (p 0.03271). Only two heterogeneity, harbored one G12C tumor, but G12V lesion, other G12A lesion WT metastasis. Conclusions We show and/ cancer indicating heterogeneity. Our suggest that sampling either (pre- posttherapeutical tissue) may valid initial evaluation predicting anti-EGFR guiding clinical decisions.